

REMARKS

The claims are 1-11, 16-19, 21-23, 27, and 31, with claims 1, 18, 22 and 31 being independent. Claims 12-15, 20, 24-26, 28-30 and 32 have been cancelled without prejudice or disclaimer. Claims 1 and 31 have been amended. Claim 1 has been amended to correct a typographical error, wherein the second recitation of R^g was changed to R^f. Support for the amendment of the last line of Claim 1 may be found in the specification at page 6, line 15. Claim 31 has been amended to cancel the recitation of selected compound species and to recite each of the remaining species on a separate line.


Applicants note that the Examiner considers claims 1-11, 16-19, 21-23, and 27 to be allowable.

Claim 31 had been objected to for formal matters and rejected under 35 U.S.C. 102(b) as allegedly anticipated by Miller et al. Applicants respectfully submit that amendment of claim 31 has placed the claim in condition for allowance.

If the Examiner has any remaining objections or concerns, the Examiner is respectfully requested to contact Applicants' undersigned agent to resolve such issues and advance the case to issue.

Authorization is hereby granted to charge Deposit Account 19-2570 any fees that may be required to obtain entry and consideration of this paper.

Respectfully submitted,



Kathryn L. Sieburth
Attorney for Applicants
Registration No. 40,072

GLAXOSMITHKLINE
Corporate Intellectual Property - UW2220
P.O. Box 1539
King of Prussia, PA 19406-0939
Phone (610) 270-5012
Facsimile (610) 270-5090
N:\KLS\Cases\pu60173\us NATL\ROA_8_15_07.doc